Résumé
Palmitoylethanolamide (PEA) is a molecule naturally synthesized by the body. It is involved in various processes regulating inflammation, pain, stress, sleep, and immunity. If the interest of the external contribution of PEA has been demonstrated in many clinical studies, its physico-chemical properties make it poorly soluble in water and does not allow a good bioavailability of the molecule administrated orally. This thesis focuses on four methods used for absorption optimization: the use of prodrugs, micronization, encapsulation and liposomal formulation. Each of these methods has advantages and disadvantages such as industrial or economic feasibility or compliance with regulatory standards for use in dietary supplements. Studies on the improvement of bioavailability and efficacy of these formulations are generally favorable. This work must be continued and extended to all the pharmacokinetic parameters of these new formulations of PEA administered orally.